Affiliation:
1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
2. Division of Hematology-Oncology, Department of Internal Medicine, University of Minnesota, Minneapolis, MN
Abstract
Abstract
Telemedicine represents an established mode of patient care delivery that has and will continue to transform cancer clinical research. Through telemedicine, opportunities exist to improve patient care, enhance access to novel therapies, streamline data collection and monitoring, support communication, and increase trial efficiency. Potential challenges include disparities in technology access and literacy, physical examination performance, biospecimen collection, privacy and security concerns, coverage of services by insurance, and regulatory considerations. Coupled with artificial intelligence, telemedicine may offer ways to reach geographically dispersed candidates for narrowly focused cancer clinical trials, such as those targeting rare genomic subsets. Collaboration among clinical trial staff, clinicians, regulators, professional societies, patients, and their advocates is critical to optimize the benefits of telemedicine for clinical cancer research.
Publisher
Ovid Technologies (Wolters Kluwer Health)